

VERIFICATION OF TRANSLATION

I, Mariko Ogura

of 6th Fl., Kantetsu Tsukuba-Science-City Bldg. 1-1-1, Oroshi-machi, Tsuchiura, Ibaraki,
JAPAN

declare as follows:

1. That I am well acquainted with both the English and Japanese languages, and
2. That the attached document is a true and correct translation of a certified copy of the following application, which was made by me to the best of my knowledge and belief of.

Japanese Patent Application No. 2002-164834

Entitled: "METHODS FOR PRODUCING ANTIBODIES"

Filed on June 5, 2002

October 13, 2006

Date

Kazumi Kakinuma

Kazumi Kakinuma

【Name of Document】 APPLICATION FOR PATENT

【Identification Number】 C1-A0210

【Filing Date】 June 5, 2002

【Addressee】 Esq. Commissioner of the Patent Office

【International Patent Classification】 A61K 39/395

【Inventor】

【Address】 16-5, Shimouma 4-chome, Setagaya-ku, Tokyo

【Name】 Tatsuhiko Kodama

【Inventor】

**【Address】 c/o CHUGAI SEIYAKU KABUSHIKI KAISHA,
135, Komakado 1-chome, Gotenba-shi, Shizuoka**

【Name】 Kou-ichi Jishage

【Inventor】

**【Address】 c/o CHUGAI SEIYAKU KABUSHIKI KAISHA,
135, Komakado 1-chome, Gotenba-shi, Shizuoka**

【Name】 Nobuo Kamada

【Inventor】

**【Address】 c/o CHUGAI SEIYAKU KABUSHIKI KAISHA,
135, Komakado 1-chome, Gotenba-shi, Shizuoka**

【Name】 Yoshiki Yamada

【Applicant】

【Identification Number】 000003311

【Name or Appellation】 CHUGAI SEIYAKU KABUSHIKI KAISHA

【Attorney】

【Identification Number】 100102978

【Patent Attorney】

【Name or Appellation】 Hatsushi Shimizu

【Nominated Attorney】

【Identification Number】 100108774

【Patent Attorney】

【Name or Appellation】 Kazunori Hashimoto

【Payment】

【Registration Number】 041092

【Amount】 21000 yen

【List of Attached Documents】

【Name of Document】 Specification 1

【Name of Document】 Drawings 1

【Name of Document】 Abstract 1

【Proof】 Necessary

[Document Name] Specification

[Title of the Invention] METHODS FOR PRODUCING ANTIBODIES

[Claims]

5 [Claim 1] A method for producing an antibody that recognizes a target antigen, wherein the method comprises the step of immunizing a non-human animal that has immunotolerance to a background antigen comprised in an immunogen, wherein the immunogen comprises both the target antigen and the background antigen.

10 [Claim 2] The method of claim 1, wherein immunotolerance is induced artificially.

[Claim 3] The method of claim 1, wherein the non-human animal is a transgenic non-human animal.

[Claim 4] A method for producing an antibody against a target antigen, wherein the method comprises the steps of:

15 (a) preparing an immunogen comprising the target antigen and a background antigen;

(b) producing a transgenic non-human animal into which a gene encoding the background antigen is introduced; and

20 (c) administering the immunogen of (a) to the transgenic non-human animal of (b).

[Claim 5] The method of claim 4, wherein the immunogen is a virus particle or a part thereof.

[Claim 6] The method of claim 5, wherein the virus is a baculovirus.

25 [Claim 7] The method of claim 4, wherein the target antigen is a membrane protein.

[Claim 8] The method of claim 6, wherein the background antigen is gp64.

30 [Claim 9] The method of claim 4, wherein the non-human animal is a mouse.

[Claim 10] An antibody that is produced by the method of any one of claims 1 to 9.

35 [Claim 11] A chimeric antibody between a non-human animal and human, or a humanized antibody, produced using the antibody of claim 10.

[Claim 12] A transgenic non-human animal into which genes

encoding a viral envelope protein are introduced to produce antibodies against antigens comprising the viral proteins.

[Claim 13] The transgenic non-human animal of claim 12, wherein the virus is a baculovirus.

5 [Claim 14] The non-human animal of claim 13, wherein the viral envelope protein is gp64.

[Claim 15] The non-human animal of claim 12, wherein the non-human animal is a mouse.

[Claim 16] A method for producing a non-human immunized animal,
10 wherein the method comprises the step of producing a transgenic non-human animal into which a gene encoding a background antigen is introduced.

[Claim 17] A non-human immunized animal for obtaining an antibody against a target antigen comprising a background antigen,
15 wherein the animal is produced by the method of claim 16.

[Claim 18] A method for producing an antibody against PepT1, wherein the method comprises the steps of:

- (a) preparing a baculovirus that expressibly comprises a DNA which encodes PepT1 or a fragment thereof;
- 20 (b) infecting a host cell with the baculovirus of (a) to obtain a budding virus that expresses PepT1 or a fragment thereof;
- (c) producing a transgenic non-human animal into which a gene encoding a baculovirus membrane protein gp64 is introduced;
- (d) immunizing the transgenic non-human animal of (c) with a fraction
25 comprising the budding virus of (b) or PepT1 or its fragment; and
- (e) recovering the antibody-recognizing PepT1 from the immunized animal.

[Claim 19] An antibody that binds to the extracellular region of PepT1.

30 [claim 20] The antibody of claim 19, wherein PepT1 is human PepT1.

[claim 21] An antibody that binds to the extracellular region of human PepT1, wherein the antibody is obtained by immunization using human PepT1.

35 [claim 22] The antibody of claim 21, wherein the human PepT1 has transport activity.

[claim 23] The antibody of claim 21, wherein the human PepT1 is full-length human PepT1.

[Detailed Description of the Invention]

[0001]

5 [Technical Field of Industrial Application]

This invention relates to methods for producing antibodies. This invention also relates to the antibodies obtained by the methods of this invention. This invention further relates to transgenic non-human animals useful for the production of antibodies generated
10 by the methods of this invention.

[0002]

[Prior Art]

Antibodies are useful as therapeutic agents, diagnostic agents, or reagents for various diseases. Many kinds of antibodies have been
15 isolated to date. General methods for producing antibodies comprise the steps of administering antigens to mammals such as mice; and obtaining antibodies derived from the serum of these animals. However, subject antibodies are not always obtained efficiently by antibody production methods, as in the following cases, for example:
20 • when a small quantity of antigen is used to immunize mammals; or
• when an insufficiently purified antigen is used to immunize mammals.

Therefore, when immunizing, it is desirable to prepare a large quantity of a sufficiently purified antigen. Practically, however, many antigens are difficult to purify or to sufficiently prepare.
25 Thus, the step of antigen preparation has often prevented antibody production.

[0003]

Membrane proteins are one example of antigens for which immunogens are difficult to prepare. Generally, membrane proteins
30 are often difficult to highly express or sufficiently purify. These difficulties have been an obstacle in obtaining antibodies against membrane proteins.

[0004]

Attention has been paid to methods that use baculoviruses to
35 express large quantities of membrane proteins. By introducing a gene that encodes a subject membrane protein into a baculovirus genome,

the subject membrane protein is expressed on the membrane surface of the budding baculovirus (WO 98/46777, Unexamined Published Japanese Patent Application No. (JP-A) 2001-333773). Using these methods enables expression of a large quantity of a subject membrane protein on a viral membrane surface.

[0005]

However, in addition to exogenous membrane proteins, baculovirus-derived membrane proteins are also expressed on the membrane surface of the baculoviruses thus obtained. Thus, when budding baculoviruses are used as antigens, antibodies against baculovirus-derived membrane proteins may also be produced. Accordingly, it has been difficult to efficiently produce antibodies against subject membrane proteins by using known immunization methods.

[0006]

For example, immunization using budding baculoviruses as antigens often induces antibodies that recognize gp64. The membrane proteins of baculoviruses comprise large quantities of gp64. In addition, due to gp64's high antigenicity, immunized animals can easily recognize gp64 as "nonself". Consequently, budding baculoviruses can be thought to preferentially induce anti-gp64 antibodies.

[0007]

Therefore, when using membrane proteins as antigens, the subject membrane proteins expressed on the baculovirus membrane surface must be sufficiently purified. However, purifying exogenous membrane proteins from budding baculoviruses is generally difficult. Thus, it can be said that sufficient quantities of highly purified membrane proteins cannot be practically obtained for use in immunization. Using conventional methods to obtain target antibodies for these difficult-to-purify antigens has been difficult.

[0008]

[Problems to be Solved by the Invention]

An objective of the present invention is to solve the above-described problems. In other words, an objective of this invention is to provide methods for producing antibodies that enable

target antibodies to be easily obtained. In addition, an objective of this invention is to provide transgenic non-human animals that efficiently produce subject antibodies.

[0009]

5 [Means to Solve the Problems]

To solve the above-described problems, the inventors focused on antigens that are comprised in immunogens and that interfere with the production of subject antibodies. Then, the inventors thought that a subject antibody could be easily obtained by using immunized
10 animals whose immune response to such interfering antigens is repressed. Furthermore, the inventors found that the above-described problems can be solved by utilizing immunotolerance to the antigens that interfere with production of the subject antibodies, to control the immune responses of the immunized animals,
15 and thereby complete the present invention.

Specifically, the present invention relates to methods for producing antibodies, transgenic non-human animals useful for these methods, and methods for producing these non-human animals. Specifically, the present invention provides the following:

20 [1] A method for producing an antibody that recognizes a target antigen, wherein the method comprises the step of immunizing a non-human animal that has immunotolerance to a background antigen comprised in an immunogen, wherein the immunogen comprises both the target antigen and the background antigen.

25 [2] The method of [1], wherein immunotolerance is induced artificially.

[3] The method of [1], wherein the non-human animal is a transgenic non-human animal.

30 [4] A method for producing an antibody against a target antigen, wherein the method comprises the steps of:

(a) preparing an immunogen comprising the target antigen and a background antigen;

(b) producing a transgenic non-human animal into which a gene encoding the background antigen is introduced; and

35 (c) administering the immunogen of (a) to the transgenic non-human animal of (b).

- [5] The method of [4], wherein the immunogen is a virus particle or a part thereof.
- [6] The method of [5], wherein the virus is a baculovirus.
- [7] The method of [4], wherein the target antigen is a membrane protein.
- [8] The method of [6], wherein the background antigen is gp64.
- [9] The method of [4], wherein the non-human animal is a mouse.
- [10] An antibody that is produced by the method of any one of [1] to [9].
- [11] A chimeric antibody between a non-human animal and human, or a humanized antibody, produced using the antibody of [10].
- [12] A transgenic non-human animal into which genes encoding a viral envelope protein are introduced to produce antibodies against antigens comprising the viral proteins.
- [13] The transgenic non-human animal of [12], wherein the virus is a baculovirus.
- [14] The non-human animal of [13], wherein the viral envelope protein is gp64.
- [15] The non-human animal of [12], wherein the non-human animal is a mouse.
- [16] A method for producing a non-human immunized animal, wherein the method comprises the step of producing a transgenic non-human animal into which a gene encoding a background antigen is introduced.
- [17] A non-human immunized animal for obtaining an antibody against a target antigen comprising a background antigen, wherein the animal is produced by the method of [16].
- [18] A method for producing an antibody against PepT1, wherein the method comprises the steps of:
- (a) preparing a baculovirus that expressibly comprises a DNA which encodes PepT1 or a fragment thereof;
 - (b) infecting a host cell with the baculovirus of (a) to obtain a budding virus that expresses PepT1 or a fragment thereof;
 - (c) producing a transgenic non-human animal into which a gene encoding a baculovirus membrane protein gp64 is introduced;
 - (d) immunizing the transgenic non-human animal of (c) with a fraction comprising the budding virus of (b) or PepT1 or its fragment; and

(e) recovering the antibody-recognizing PepT1 from the immunized animal.

[19] An antibody that binds to the extracellular region of PepT1.

[20] The antibody of [19], wherein PepT1 is human PepT1.

5 [21] An antibody that binds to the extracellular region of human PepT1, wherein the antibody is obtained by immunization using human PepT1.

[22] The antibody of [21], wherein the human PepT1 has transport activity.

[23] The antibody of [21], wherein the human PepT1 is full-length
10 human PepT1.

[0010]

[Mode for Carrying Out the Invention]

This invention relates to methods for producing antibodies which recognize target antigens, wherein the methods comprise the
15 step of immunizing immunogens that comprise a target antigen and a background antigen, to non-human animals with immunotolerance to the background antigen comprised in the immunogen.

[0011]

The term "target antigen" denotes antigens recognized by
20 subject antibodies. The target antigens can be selected from any compound comprising antigenicity. Specifically, proteins, sugar chains, lipids, or inorganic substances are known to comprise antigenicity. The target antigens may be naturally occurring or artificially synthesized. The artificially synthesized target
25 antigens comprise recombinant proteins prepared by genetic engineering technology, and many kinds of chemically-synthesized organic compounds.

[0012]

According to the present invention, the term "background
30 antigen" denotes substances comprising antigenic determinants for which antibody generation is not desired, or denotes the antigenic determinants themselves. For example, any antigenic substance that is not a target antigen, but which is contaminated within the target antigen, is a background antigen. Typical background antigens are
35 proteins contaminated within crudely purified target antigens. More specifically, host cell-derived proteins in a recombinant protein

are examples of background antigens.

[0013]

Generally, a background antigen is an antigenic substance other than a target antigen. According to the present invention, however, 5 antigenic determinants present on target antigen molecules may also be referred to as background antigens. For example, if an antigenic determinant for which antibody generation is undesired is present on a target antigen molecule, the antigenic determinant is defined as a background antigen. Moreover, the background antigens of the 10 present invention include substances that comprise antigenic determinants as background antigens, yet do not comprise target antigens.

[0014]

According to the present invention, preferable background 15 antigens are proteins, peptides, sugars, or glycoproteins. Of these, proteins or peptides are particularly preferable background antigens. The term "peptide" denotes, for example, polypeptides that consist of 100 or fewer amino acid residues. The term "protein" includes "peptide".

20 [0015]

According to the present invention, the term "immunotolerance" denotes a condition in which an immune response, specific to an antigen that is an immunotolerance target (an immunotolerance antigen), is lost or decreased. When the level of a subject's immune response to 25 an immunotolerance antigen is reduced compared to that of a normal immunized animal, the subject can be regarded to comprise immunotolerance against the immunotolerance antigen. For example, when the amount of an antibody generated against an immunotolerance antigen is decreased in response to the administration of an 30 immunotolerance antigen, the level of immune response is then considered to be low. Immunotolerance levels are not limited.

[0016]

In addition, the term "immunotolerance antigen" denotes antigenic substances for which a subject's immune response is 35 decreased. Also, according to the present invention, a reduced level of a specific immune response to an immunotolerance antigen denotes

that the degree by which the immune response to the immunotolerance antigen has decreased is greater than for other antigens. Thus, even if the immune response to antigens other than the immunotolerance antigen is decreased, immunotolerance has been established if the level of decrease in immune response to other antigens is less than the level of decrease for the immunotolerance antigen. Also, according to the present invention, immunotolerance includes cases of immunotolerance to antigenic substances other than background antigens. Subjects which are immunotolerant to multiple antigens may also be used in the present invention, as long as they have an immune response to a target antigen. On the other hand, cases of immunodeficiency where the level of actual immune response is decreased are not preferable, since generation of antibodies against target antigens cannot be expected.

15 [0017]

In the present invention, non-human animals that comprise immunotolerance to a background antigen are used as immunized animals. Non-human animals comprising artificially induced immunotolerance are preferably used. For example, non-human animals comprising immunotolerance can be generated as below:

[0018]

First, a gene encoding a background antigen can be introduced into a non-human animal to generate a transgenic animal that comprises the gene encoding the background antigen. Transgenic animals thus obtained have immunotolerance to the expression product of the introduced gene (the background antigen). Immunotolerance can also be induced by multiple administrations of an immunotolerance antigen (a background antigen) to non-human animals in the fetal stage or shortly after birth.

30 [0019]

Methods for administering antigens as immunotolerance antigens to non-human animals in the fetal stage or shortly after birth can include methods for administering the antigenic substances themselves into non-human animals. Alternatively, indirect methods for administering immunotolerance antigens may also be applied. For example, subject immunotolerance antigens are administered by *in vivo*

expression of genes that encode the immunotolerance antigens. Such methods include methods for directly administering an antigen-coding DNA (naked DNA methods), for transplanting antigen-expressing cells into non-human animals, methods using viral vectors, and methods using
5 DNA vaccines.

[0020]

Of these methods, transgenic non-human animals which preserve a gene encoding an immunotolerance antigen in an expressible state are preferred as the non-human animals comprising immunotolerance
10 of the present invention. The transgenic animals comprise in their body an immunotolerance antigen that was originally an exogenous protein prior to the maturation of immune functions. Therefore, it is highly possible that the immune functions of the transgenic animals recognize the immunotolerance antigen as being completely endogenous.
15 Thus, the use of such transgenic non-human animals is advantageous in inducing immunotolerance in the present invention. The transgenic animals, into which immunotolerance antigens are introduced, produce few antibodies to immunotolerance antigens, as shown in Examples.

[0021]

20 In addition, the immunotolerant traits of the transgenic animals can be inherited by their progeny. Therefore, once a transgenic non-human animal has been established for the present invention, immunized animals comprising the same traits can be stably provided.

25 [0022]

This invention also relates to transgenic non-human animals into which genes encoding a viral envelope protein are introduced to produce antibodies against antigens comprising the viral proteins. Moreover, this invention relates to use of transgenic non-human
30 animals into which a gene encoding the viral envelope protein is introduced, as immunized animals. Furthermore, this invention relates to methods for producing non-human immunized animals, where the methods comprise the step of generating a transgenic non-human animal into which a gene encoding a background antigen has been
35 introduced.

Many kinds of transgenic non-human animals into which different

kinds of genes have been introduced are known in the art. However, animals into which an exogenous gene has been introduced are not known to be useful as immune animals for a target antigen that comprises a background antigen.

5 [0023]

Since an animal in which a gene that encodes a target antigen protein has been deleted, (so called knock-out animals), does not comprise the target antigen protein congenitally, a target antibody can be obtained by administering the target antigen to the knock-out
10 animal, even if the target antigen is highly homologous to a protein present in the immunized animal. Moreover, it is possible to obtain an animal which is deficient in a target antigen, and which expresses an immunotolerant antigen, by crossing the target antigen-deficient animal with the transgenic animal of the present invention.

15 Genes coding for background antigens can also be introduced into a fetal or post-fetal non-human animal in a fetal period or thereafter, by using naked DNA methods, DNA vaccine methods, or methods for transplanting cells that express background antigens. Non-human animals thus obtained are also included in the transgenic non-human
20 animals of the present invention.

[0024]

There is no limitation as to the number of background antigens used to induce immunotolerance in the immunotolerant non-human animals of the present invention. That is, a non-human animal, in
25 which immunotolerance to at least one background antigen has been induced, can be used in an antibody-production method of the present invention. Non-human animals in which immunotolerance to multiple background antigens has been induced can also be used as immunized animals.

30 [0025]

In the immunized animals, it is not always important to suppress production of antibodies against all of the background antigens that might be comprised in an immunogen. Production of antibodies that recognize background antigens is acceptable as long as they do not
35 interfere with the production and isolation of an antibody against a target antigen. Therefore, for example, an immunized animal in

which immunotolerance has only been induced to a major background antigen can be used as a preferable immunized animal in the present invention.

[0026]

5 In the present invention, non-human animals comprise, for example, monkeys, pigs, dogs, rats, mice, and rabbits. For example, rodents such as rats, mice, and hamsters are preferable as non-human animals. To induce immunotolerance by preparing transgenic animals, it is advantageous to use non-human animals which mature fast and
10 for which gene manipulation technologies have been established, such as rodents. Mice in particular are non-human animals that meet these requirements at a high level.

[0027]

This invention relates to transgenic non-human animals into
15 which genes coding for viral envelope proteins have been introduced. Transgenic non-human animals of the present invention are useful in immunization against a target antigen in the presence of viral envelope proteins. Viral envelope proteins in this invention are proteins that make up an envelope of a budding virus. In baculoviruses,
20 the protein called gp64 is an envelope protein.

[0028]

For example, a transgenic non-human animal with immunotolerance to the baculoviral gp64 is useful as an immune animal for an immunogen produced by the baculovirus expression system. Many kinds of
25 proteins can be produced by the baculovirus expression system. Therefore, by using these transgenic animals and baculovirus expression systems in combination, target antibodies can be easily obtained by using a variety of protein antigens as target antigens.

[0029]

30 Immunogens of the present invention comprise both target antigens and background antigens. As described above, there is no particular limitation as to the substances constituting target antigens or background antigens. When an animal with immunotolerance is produced by introduction of a gene encoding a background antigen,
35 the background antigen is a protein. Immunogens may include substances other than target antigens and background antigens.

[0030]

Furthermore, there is no limitation as to the types of background antigens that comprise the immunogens of the present invention. Therefore, immunogens comprising multiple kinds of background antigens, which may interfere with the production of antibodies against a target antigen, can also be used in the present invention. The presence of these background antigens is not a problem, as long as an immunized animal shows immunotolerance to each background antigen. Alternatively, background antigens which do not substantially interfere with the production of antibodies against a target antigen may be comprised in an immunogen, regardless of whether or not an immunized animal is immunotolerant to them.

[0031]

Generally, a target antigen comprises substances derived from biological materials. Biological materials are complex mixtures comprising various components. Thus, target antigens are usually prepared using various mixtures as starting materials. Therefore, it is difficult to obtain highly-purified target antigens. In other words, it involves a lot of time and effort to isolate a large quantity of a highly pure target antigen. Practically, it is almost inevitable that an immunogen contains substances other than the target antigen.

[0032]

Immunogens of the present invention specifically include cells, cell cultures, cell lysates, viruses, or unpurified antigens. Parts of cells or viruses can be used as immunogens, as well as whole cells or whole viruses. For example, cell membranes or virus envelopes can be used as immunogens. When a cell or virus is used as an immunogen, a gene coding for a subject antigen can be artificially introduced into the cell or virus by recombinant gene technology that artificially expresses the subject antigen.

[0033]

One preferable immunogen of the present invention is a viral particle or part thereof. Viruses are comprised of relatively simple components, including nucleic acids, and limited proteins, saccharides, and such. Consequently, the types of background antigens that may interfere with target antigen isolation are also

limited. In sum, inducing immunotolerance against a limited number of background antigens in an animal to be immunized would be enough to carry out a method for producing antigen of the present invention.

[0034]

5 In the present invention, baculoviruses, for example, are preferred among the viruses that can be used as immunogens. Baculoviruses are insect viruses that comprise a structure whereby a double-stranded DNA genome is covered with a capsid protein. Expression systems using Nucleopolyhedrovirus (NPV), a type of
10 baculovirus, are useful as systems for expressing exogenous genes. NPV comprises strong promoter activity. Therefore, any protein can be produced in large quantities by inserting an exogenous gene into the NPV genome. Specifically, strong expression of any exogenous gene is induced by recombinantly substituting the gene coding for
15 the protein called polyhedron with the exogenous gene.

[0035]

Any exogenous genes can be introduced into a baculovirus. For example, a gene encoding a membrane protein can be used as an exogenous gene.

20 By using baculoviruses, a subject membrane protein can be expressed along with a viral envelope protein in a form that retains that structure. Another big advantage of the baculovirus expression system is that the expressed products are easily recovered as budding viral particles.

25 [0036]

Membrane proteins include many biologically important molecules, such as receptors and transporters. However, many membrane proteins maintain their structure by being located in a cell membrane. In addition, membrane proteins are often
30 post-translationally modified with sugar chains or lipids. Therefore, there are often cases where expression systems utilizing prokaryotes such as *E.coli* cannot reproduce membrane proteins in their *in situ* structure.

[0037]

35 As methods for expressing exogenous proteins such as membrane proteins on viral envelopes, for example, the method of W098/46777

or Loisel et al. for expressing envelope proteins using budding baculoviruses can be used (Loisel, T.P. et al., Nature Biotech. 15: 1300-1304 (1997)). More specifically, a recombinant vector for insect cells comprising a gene encoding an exogenous protein is
5 constructed, and inserted, along with baculoviral DNA, into insect cells such as Sf9. The exogenous protein encoded by the recombinant vector is then expressed on mature viral particles (virions), which are released by infected cells to the outside of cells prior to infected cell death. Recombinant viruses that express the exogenous
10 protein can thus be obtained.

[0038]

In the present invention, a budding virus is a virus that is released from infected cells by budding. Generally, viruses covered with an envelope can bud from cells infected with these viruses, and
15 are released continuously, even when the cells have not been destroyed. On the other hand, adenoviruses that are not covered by an envelope, and herpes viruses that are covered by a nuclear envelope, are released from the cells all at once, upon cell destruction. Budding viruses are particularly preferable in the present invention. In addition,
20 those skilled in the art can suitably select hosts to be infected with a recombinant virus, depending on the type of virus used, so long as viral replication is possible in the host. For example, insect Sf9 cells can be used when using baculoviruses. Generally, protein expression systems using baculoviruses and insect cells can be useful
25 because modifications such as fatty acid acetylation or glycosylation are carried out at the same time as translation or post-translation, in the same way as in mammalian cells. In addition, the expression level of heterologous proteins in such systems is greater than that in mammalian cell systems (Luckow V.A. and Summers M.D., Virol. 167:
30 56 (1988)).

[0039]

The viruses expressing exogenous proteins can be obtained by, for example, culturing a host that has been infected with a recombinant virus comprising a gene that encodes an exogenous protein.
35 Alternatively, using methods such as the above-mentioned methods of WO 98/46777 and Loisel et al (Loisel, T.P. et al., Nature Biotech.

15: 1300-1304 (1997)), a recombinant vector encoding an exogenous protein can be inserted into an insect cell along with a baculovirus, and exogenous proteins can be expressed on the envelope of the baculovirus released outside of the cell. In addition, using methods
5 like that of Strehlow et al. (D. Strehlow et al., Proc. Natl. Acad. Sci. USA. 97: 4209-4214 (2000)), packaging cells such as PA317 can be infected with recombinant Moloney murine leukemia viruses, which are constructed using vectors derived from Moloney viruses introduced with exogenous protein-encoding genes, and the exogenous proteins
10 can be expressed on the envelope of viruses released outside of the cells. However, the viruses of the present invention that express exogenous proteins, useful as immunogens, are not limited to those that are constructed using the above methods.

[0040]

15 Recombinant viruses constructed as described above can be purified using known methods. For example, known methods for purifying viruses include augmented density gradient centrifugation (Albrechtsen et al., J. Virological Methods 28: 245-256 (1990); Hewish et al., J. Virological Methods 7: 223-228 (1983)), size exclusion
20 chromatography (Hjorth and Mereno-Lopez, J. Virological Methods 5: 151-158 (1982); Crooks et al., J. Chrom. 502: 59-68 (1990); Mento S.J. (Viagene, Inc.) 1994 Williamsburg Bioprocessing Conference), affinity chromatography using monoclonal antibodies, sulphated fucose-containing polysaccharides and the like (Najayou et al., J.
25 Virological Methods 32: 67-77 (1991); Diaco et al., J. Gen. Virol. 67: 345-351 (1986); Fowler, J. Virological Methods 11: 59-74 (1986); TOKUSAIHYOU No. 97/032010 (Unexamined Publication of Japanese National Phase Patent Application)), and DEAE ion exchange chromatography (Haruna et al., Virology 13: 264-267 (1961)). Thus,
30 purification can be carried out using the above methods or combinations thereof.

[0041]

In the present invention, there is no limitation as to the kind of background antigen which becomes an immunotolerance antigen for
35 use as an antigen to induce immunotolerance in immune animals. Preferably, the immunotolerance antigens are such substances that

are comprised in an immunogen in a large quantity, or that have a strong antigenicity. For example, when a baculovirus is used as an immunogen, gp64 is preferably used as an immunotolerance antigen. Gp64 is a major background antigen, which is expressed in large quantities on the surface of the viral envelope, and which is susceptible to being recognized as non-self by animals immunized with baculoviruses.

[0042]

Baculoviruses comprise characteristics that are preferable in an expression system for exogenous proteins. On the other hand, use of an expression product produced by this system as an immunogen, it is accompanied by production of background antigens, which can be a drawback. In particular, when using a baculovirus expression system to produce a membrane protein that is used as an immunogen, the presence of gp64 is a big problem. gp64 is comprised in large amounts in viral envelope proteins. Thus, contamination of an exogenous membrane protein with gp64 is inevitable.

[0043]

By using the antibody-production methods of the present invention, the inhibitory effect that background antigens have on the acquisition of antibodies against a target antigen can be suppressed. Consequently, the use of this invention enables sufficient application of the advantages of a baculovirus expression system as an exogenous protein expression system, even in the preparation of immunogens.

[0044]

In the present invention, naturally occurring viruses or parts thereof can also be used as immunogens. Development of an antibody that recognizes a specific antigenic determinant of a naturally occurring virus is important to the specific detection of the virus, and also to prevention of or therapy for infection by that virus. Whereas antibodies against major antigens can be easily produced, it is often difficult to acquire an antibody that recognizes a specific antigenic determinant. This situation is common to the above described case in which a baculovirus expression product is used as an immunogen.

[0045]

When using a naturally occurring virus as an immunogen of the present invention, a gene coding for a protein that will act as a background antigen, selected from proteins that constitute the virus,
5 is introduced into a non-human animal to prepare a transgenic animal. Alternatively, viral particles themselves, or parts thereof that comprise a target antigen, are used as immunogens. In this way, an antibody that recognizes a target antigen can be efficiently obtained.

[0046]

10 For example, the surface antigens of influenza viruses are important antigens that determine the viral strain. If antibodies that recognized the surface antigens specific to each influenza virus strain could be easily obtained, this would be useful to identification of the virus, as well as in the prevention of or therapy
15 for infection by the virus. However, when using the viral particles themselves as immunogens, antibodies that recognize structures common to the viruses will also be produced in large quantities.

[0047]

Antibodies that recognize surface antigens specific to each
20 viral strain can be efficiently obtained by using a transgenic non-human animal of the present invention, which has immunotolerance to an envelope protein that is common to the influenza viruses. In other words, this invention can be also carried out using surface antigens that are specific to each strain of a virus as target antigens,
25 and using structures that are common to the viruses as background antigens.

[0048]

A preferable embodiment of the antibody-production methods of the present invention is described below. In this embodiment,
30 membrane proteins are used as target antigens. For example, human-derived membrane proteins can be used as the membrane proteins.

First of all, a target protein is expressed on the surface of the baculovirus envelope, and this baculovirus is used as an immunogen. As a method for expression the membrane protein using baculoviruses,
35 for example, the methods for expressing membrane proteins using budding baculoviruses, disclosed in WO 98/46777, JP-A 2001-333773,

Loisel et al. (T. P. Loisel et al., Nature Biotech. 15: 1300-1304 (1997)), can be used.

[0049]

In more detail, a recombinant vector for insect cells is
5 constructed to comprise a gene encoding a membrane protein. This
vector is then introduced into insect cells along with the baculovirus
DNA. Sf9 cells and such are used as the insect cells. The membrane
protein encoded by the recombinant vector is expressed in mature viral
10 particles (virions) released extracellularly from the infected cells
prior to cell death. Therefore, budding baculovirus particles that
express the membrane protein (target antigen) may be obtained by
harvesting mature virus particles. Methods for recovering budding
baculovirus from cultured cells are also known in the art. The thus
15 obtained budding baculoviruses that express a membrane protein
(target antigen) are used as immunogens of the present invention.

[0050]

As described above, the surface of the baculovirus envelope
expresses not only a membrane protein (the target antigen), but also
another envelope protein derived from a baculovirus. In particular,
20 gp64 is expressed in large quantities on the surface of baculoviruses,
and also has strong antigenicity. Therefore, when immunization is
carried out using a budding baculovirus, anti-gp64 antibodies are
also produced, and thus antibodies to the membrane protein (target
antigen) cannot be efficiently obtained.

25 [0051]

Accordingly, in the present invention, an animal that expresses
gp64 is used as an animal to be immunized. Specifically, a transgenic
animal that expresses gp64 is produced by introducing a vector that
comprises a gene encoding gp64 into an animal. The transgenic animals
30 of the present invention are non-human animals. For example, a
transgenic mouse into which the gp64 gene has been introduced can
be used as an animal to be immunized in the present invention.

[0052]

In the present invention, these transgenic mice are immunized
35 with the budding baculovirus particles obtained as described above.
Since the gp64-expressing transgenic mice endogenously express gp64,

they comprise immunotolerance to gp64, which acts as a background antigen. In other words, production of anti-gp64 antibodies in the gp64-expressing transgenic mice is suppressed when the mice are immunized with the budding baculovirus particles. As a result, antibodies against a target membrane protein can be produced efficiently.

[0053]

Methods for producing transgenic mice are known in the art. For example, transgenic mice can be obtained according to the methods described in Proc. Natl. Acad. Sci. USA 77: 7380-7384 (1980). Specifically, subject genes are introduced into mammalian totipotent cells, and then the cells are brought up into individuals. A subject transgenic mouse can be obtained from the individuals thus obtained by screening for individuals in which the introduced gene has been integrated into both somatic cells and germ cells. Fertilized eggs, early embryos, and cultured cells with multipotency such as ES cells, and such, can be used as the totipotent cells for introducing a gene.

More specifically, transgenic mice can be prepared, for example, by the method in Examples.

[0054]

The antibody-production methods of the present invention can be used to produce polyclonal and monoclonal antibodies. Polyclonal antibodies can be obtained by recovering antibodies to the target antigen from an immunized animal. Alternatively, monoclonal antibody-producing cells can be obtained by cloning an antibody-producing cell derived from an immunized animal.

Furthermore, by using antibodies or genes thereof obtained from an immunized animal such as mice, chimeric antibodies of human and immunized animals, or humanized antibodies can be obtained. Methods for producing these antibodies that comprise modified structures are also known in the art.

[0055]

Furthermore, this invention relates to the antibodies obtained by the methods of the present invention. The antibodies of the present invention comprise any kind of antibody that can be obtained by a procedure comprising a method as described above. Consequently, this

invention includes, for example, monoclonal antibodies, polyclonal antibodies, chimeric antibodies of human and immunized animals, humanized antibodies, and human antibodies. For example, a transgenic mouse whose immune system has been substituted with that of a human is known in the art. Human antibodies can be obtained by immunizing such mice.

[0056]

Preferable antibodies in the present invention are antibodies that recognize human membrane proteins. Many membrane proteins are important as target molecules for drug discovery. However, antibodies specific to membrane proteins have been considered difficult to obtain due to purification difficulties. The present invention, however, has made it possible to efficiently obtain a subject antibody, even though the target antigen is a recombinantly-produced membrane protein that co-exists with a background antigen. For example, as a membrane protein, PepT1 is an important molecule. The nucleotide sequence and amino acid sequence of PepT1 are already known: human PepT1 (GenBank XM_007063) is described in J. Biol. Chem. 270(12): 6456-6463 (1995); and mouse PepT1 (GenBank AF205540) is described in Biochim. Biophys. Acta. 1492: 145-154 (2000)).

[0057]

Those anti-PepT1 antibodies that bind to an extracellular region of PepT1 are useful. In particular, an antibody that specifically binds to an extracellular region of PepT1 is preferable in the present invention. In the present invention, the phrase "specifically binds to an extracellular region" means the ability to immunologically discriminate extracellular regions of PepT1 from other regions. More specifically, an antibody that specifically binds to an extracellular region of PepT1 is defined as an antibody that binds to an extracellular region, but does not bind, for example, to an intracellular region or transmembrane domain of PepT1. Human PepT1 is a preferable PepT1 in the present invention. Human PepT1 includes not only PepT1s derived from humans, but also recombinant PepT1s obtained by expressing human PepT1 in a baculovirus expression system.

[0058]

The human PepT1 molecules that are used as immunogens do not have to be entire molecules, as long as they retain a target antigen structure. For example, a fragment comprising a PepT1 extracellular region can be used as an immunogen. A preferable PepT1 in the present invention is a human PepT1 that comprises transport activity, or a full-length human PepT1. A full-length human PepT1 comprising transport activity is especially preferable. The transport activity of a human PepT1 can be detected by using the activity of incorporating a substrate into a cell as an indicator. As its substrates, PepT1 is known to incorporate glycylsarcosine or such into cells. Incorporation of glycylsarcosine can be assayed by using [^{14}C] glycylsarcosine or such.

Human PepT1 is preferably expressed on the surface of a membrane (such as a viral envelope or cell membrane). The transport activity of a PepT1 expressed on the surface of a viral envelope can be detected by contacting a solution comprising viral particles with a substrate; and then monitoring the incorporation of the substrate into the viral particles.

20 [0059]

Well-known methods can be used for the methods of immunizing to obtain antibodies. Animals can be immunized with an immunogen using known methods. General methods include injecting a sensitizing antigen into a mammal by subcutaneous or intraperitoneal injection. Specifically, an immunogen is diluted with an appropriate volume of Phosphate-Buffered Saline (PBS) or physiological saline, and as desired, the suspension is mixed with an appropriate volume of a conventional adjuvant. This is emulsified and applied to the mammals. For example, Freund's complete adjuvant can be used as an adjuvant. In addition, after this, an immunogen that has been mixed with an appropriate volume of Freund's incomplete adjuvant is preferably applied several times every four to 21 days.

When immunizing an immunogen, an appropriate carrier can also be used. In this way immunization occurs, and the increased level of a desired antibody in the serum can be confirmed using conventional methods.

[0060]

When obtaining the target antibodies, an increase in the level of a desired antibody in the serum is confirmed, and blood is then collected from the immunized mammals. Serum can be separated from
5 collected blood using known methods. As polyclonal antibodies, serum comprising polyclonal antibodies can be used. Where necessary, fractions comprising polyclonal antibodies can be isolated from this serum, and this fraction can also be used.

For example, fractions only recognizing the target antigens can
10 be obtained using affinity columns coupled to the target antigens. Immunoglobulin G or M can be prepared by purifying these fractions using a protein A or protein G column.

[0061]

After confirming the increase in the level of the intended
15 antibody in the serum of a mammal that was sensitized by the above-described antigen, the antibody-producing cells are extracted from the mammal and cloned to obtain monoclonal antibodies. Spleen cells and such can be used as antibody-producing cells. Antibody-producing cells can be cloned by cell fusion methods.
20 Mammalian myeloma cells and such can be used as parent cells to be fused with the above-mentioned antibody-producing cells. Even more preferably, myeloma cells that comprise unique auxotrophy or drug resistance can be examples of useful selective markers for fusion cells (hybridoma cells).

25 [0062]

By basically following the methods known in the art, fusion cells can be obtained from the antibody-producing cells and the myeloma cells described above. Methods for producing monoclonal antibodies by using the cell fusion techniques have been established,
30 for example, by Milstein et al. (Galfre, G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46).

[0063]

The hybridoma cells produced by cell fusion techniques are selected by culturing in a selective medium. A suitable selective
35 medium can be used in accordance with the characteristic features of the myeloma cells used for the cell fusion. HAT medium (a medium

comprising hypoxanthine, aminopterin, and thymidine), for example, can be used as a selective medium. The hybridoma cells are cultured in the HAT medium for a time sufficient to kill all cells other than the intended hybridoma cells (e.g. all non-fused cells). Generally,
5 hybridoma cells can be selected by continuing culture for several days to several weeks. After selection, a standard limiting dilution method can be used to screen and clone the hybridoma cells that produce the subject antibodies.

[0064]

10 Subsequently, the hybridoma cells thus obtained are intraperitoneally transplanted into mice to obtain ascites fluid comprising the monoclonal antibodies. Monoclonal antibodies can also be purified from the ascites fluid. For example, monoclonal antibodies can be purified by ammonium sulfate precipitation methods,
15 protein A or protein G columns, DEAE ion exchange chromatography, or affinity columns coupled with a target antigen.

In addition to producing antibodies by using hybridomas, antibody-producing cells such as antibody-producing sensitized lymphocytes and such, which have been immortalized using oncogenes
20 or viruses and such, can also be used. Epstein-Barr virus (EBV) and so on can be used as a virus for immortalizing cells.

[0065]

Monoclonal antibodies obtained in this way can also be used as recombinant antibodies that were produced using gene recombination
25 technologies (for example, see Borrebaeck, C.A.K. and Larrick, J.W., Therapeutic Monoclonal Antibodies, UK, Macmillan Publishers Ltd., 1990). Recombinant antibodies can be produced by cloning the DNAs that encode them from antibody-producing cells, such as hybridomas and antibody-producing sensitized lymphocytes, then incorporating
30 these DNAs into a suitable vector, and introducing this vector into a host. The present invention also encompasses such recombinant antibodies.

[0066]

The antibodies obtained by the methods of the present invention
35 can also be antibody fragments, modified antibodies, and the like. For example, an antibody fragment can be an Fab, F(ab')₂, Fv, or a

single chain Fv (scFv) where the Fvs of an H chain and L chain are linked by a suitable linker (Huston, J.S. et al., Proc. Natl. Acad. Sci. U.S.A., (1998) 85, 5879-5883). Specifically, the antibody fragments can be obtained by treating antibodies with an enzyme such as papain or pepsin. Alternatively, genes encoding these antibody fragments are constructed, inserted into an expression vector, and expressed in appropriate host cells (see for example, Co, M. S. et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, A. H., Methods Enzymol. (1989) 178, 476-496; Pluckthun, A. and Skerra, A., Methods Enzymol. (1989) 178, 497-515; Lamoyi, E., Methods Enzymol. (1986) 121, 652-663; Rousseaux, J. et al., Methods Enzymol. (1986) 121, 663-669; Bird, R. E. and Walker, B. W., Trends Biotechnol. (1991) 9, 132-137).

[0067]

Antibodies bound to various molecules such as polyethylene glycols (PEG), can also be used as the modified antibodies. "Antibody" in the present invention also encompasses these modified antibodies. Such modified antibodies can be obtained by chemically modifying obtained antibodies. These methods have already been established in the art.

[0068]

In addition, methods for obtaining human antibodies are known. A target antibody can be obtained by immunizing transgenic animals, that comprise the entire repertoire of human antibody genes, with a target antigen (see, International Patent Application No. WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735).

[0069]

The antibodies obtained by the methods of the present invention can be chimeric antibodies comprising non-human antibody-derived variable regions, derived from the immunized animals, and human antibody-derived constant regions. In addition, they can also be humanized antibodies comprising non-human antibody-derived complementarity determining regions (CDRs) which are derived from the immunized animals, human antibody-derived framework regions (FRs), and constant regions.

[0070]

These modified antibodies can be produced using known methods. Specifically, for example, a chimeric antibody is an antibody comprising the antibody heavy chain and light chain variable regions of an immunized animal, and the antibody heavy chain and light chain constant regions of a human. A chimeric antibody can be obtained by (1) ligating a DNA encoding a variable region of an immunized animal-derived antibody to a DNA encoding a constant region of a human antibody; (2) incorporating this into an expression vector; and (3) introducing the vector into a host for production of the antibody.

[0071]

A humanized antibody, which is also called a reshaped human antibody, is a modified antibody. A humanized antibody is constructed by transplanting a complementarity determining region (CDR) of an antibody of an immunized animal, into the CDR of a human antibody. Conventional genetic recombination techniques for the preparation of such antibodies are known.

[0072]

Specifically, a DNA sequence designed to ligate a mouse antibody CDR with a human antibody framework region (FR) is synthesized by PCR, using several oligonucleotides constructed to comprise overlapping portions at their ends. A humanized antibody can be obtained by (1) ligating the resulting DNA to a DNA which encodes a human antibody constant region; (2) incorporating this into an expression vector; and (3) transfecting the vector into a host to produce the antibody (see, European Patent Application No. EP 239,400, and International Patent Application No. WO 96/02576). Those human antibody FRs that are ligated via the CDR, such that the CDR forms a favorable antigen-binding site, are selected. As necessary, amino acids in the framework region of an antibody variable region may be substituted such that the CDR of a reshaped human antibody forms an appropriate antigen-binding site (Sato, K. *et al.*, Cancer Res. (1993) 53, 851-856).

[0073]

Antibodies obtained as above can be purified until they are homogenous immunoglobulin molecules. These purification methods are

not particularly limited. Separation and purification methods conventionally used for polypeptides can be used to separate and purify the antibodies used in the present invention. For example, immunoglobulins can be separated and purified by appropriately
5 selecting and combining chromatography columns such as affinity chromatography columns, filters, ultrafiltration, salt precipitation, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing and so on (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988). The
10 concentration of the above-obtained antibodies can be determined by measuring absorbance, or by enzyme-linked immunosorbent assays (ELISA), etc.

[0074]

Protein A columns, protein G columns, and such can be used as
15 the columns for use in affinity chromatography. For example, Hyper D, POROS, Sepharose F.F. (Pharmacia) and so on are examples of the columns using protein A.

[0075]

Examples of chromatography other than affinity chromatography
20 include ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterisation: A Laboratory Course Manual. Ed Daniel R, Marshak et al., Cold Spring Harbor Laboratory Press, 1996). These chromatographies can be
25 carried out using liquid phase chromatography such as HPLC and FPLC.

[0076]

[Examples]

The present invention is specifically described herein below using Examples, however, it is not to be construed as being limited
30 thereto.

1) Construction of gp64 transgenic vector

The nucleotide sequence of gp64 and the amino acid sequence encoded by the gp64 gene are shown in SEQ ID NOs: 3 and 4, respectively (GenBank Acc No. 9627742). PCR was carried out using the gp64 gene
35 as a template, and using the following primer set: the 5' primer 64F1, which comprises an EcoRI recognition sequence and the KOZAK sequence

at its 5' terminus; and the 3' primer 64R1 (Fig. 1), which comprises an EcoRI recognition sequence at its 5' terminus. The PCR conditions are shown below:

The PCR reaction solution composition was 5 μ l of x10 ExTaq
5 buffer, 4 μ l of dNTP supplied with ExTaq, 1 μ l of 10 μ mol/l 64F1 primer,
1 μ l of 10 μ mol/l 64R1 primer, 1 μ l of 500 pg/ μ l pBac-N-blue, 0.5 μ l
of 5 units/ μ l ExTaq, and 37.5 μ l of DIW. PCR was carried out for:
5 minutes at 94°C;
25 cycles of "15 seconds at 94°C, 30 seconds at 57°C, and 30 seconds
10 at 72°C";
7 minutes at 72°C; and
4°C forever.

The amplified band was subcloned into pGEM-Teasy, and then
transformed *E. coli* DH5 α cells. After performing colony PCR using
15 T7 and SP6 primers, the nucleotide sequence of clones confirmed to
comprise the insert was analyzed with the ABI Prism377 DNA sequencer
and the BigDye Cycle Sequence kit, in combination with the T7 primer
or the SP6 primer. As a result, clones comprising the subject gene
were confirmed. A fragment comprising the gp64 gene and confirmed
20 to comprise no mutations in its nucleotide sequence was isolated from
the clones by EcoRI digestion, and then inserted into an
EcoRI-digested pCAGGS1. The resulting vector was used to transform
E. coli DH5 α cells. Cells comprising the clone as designed were
incubated in 250 ml of LB medium at 37°C overnight, and purified by
25 using the Endofree MAXI kit to obtain 581.6 μ g of plasmid.

[0077]

2) Introduction of the gene

The DNA fragment for injection was prepared as follows: The
pCAGGS vector into which the gp64 gene was inserted (pCAG-gp64, Fig.
30 2) was treated with SalI and PstI to yield a fragment (about 3.8 kb)
comprising the gp64 gene. This fragment (about 3.8 kb) was extracted
using the Gel Extraction kit (QIAGEN), and then diluted with PBS to
a concentration of 3 ng/ μ l, yielding the DNA fragment for injection.

[0078]

35 The mouse pronuclear eggs to be injected with the DNA fragment
were collected as follows: Specifically, Balb/c series female mice

(Nippon CLEA) were induced to superovulate by intraperitoneal administration of 5 international units (i.u) of PMSG, followed by intraperitoneal administration of 5 i.u of hCG 48 hours later. These female mice were mated with male mice of the same lineage. The morning
 5 after mating, the oviducts of female mice that were confirmed to have a vaginal plug were perfused to recover pronuclear eggs.

[0079]

The DNA fragments were injected into the pronuclear eggs with a micromanipulator (The latest technologies in gene targeting (gene
 10 targeting no saishin gijyutu) (Yodosha), 190-207, 2000). The DNA fragments were injected into 373 embryos of BALB/c mice. On the next day, 216 embryos that had developed to the two-cell stage were transplanted into the oviducts of recipient female mice, which were in the first day of pseudopregnancy, at a density of around ten embryos
 15 per oviduct (i.e. around 20 embryos per mouse).

The recipient female mice that did not give birth to offspring by the expected date of delivery were subjected to caesareans, and the resultant offspring were brought up by a foster parent. The results are summarized in Table 1. Fifty offspring were obtained,
 20 four of which were transgenic mice into which the gp64 gene has been introduced (referred to as Tgm below). Hereinafter, the transgenic mice obtained in the first generation are described as "Founder" mice.

[0080]

25 [Table 1]

	Viable embryos after injection/ Embryos receiving injection	Transplanted embryos	Implanted embryos	Offspring (female, male)	Weaned Offspring (female, male)	Founder
1st	59/63	55	20	9 (4, 5)	9 (4, 5)	0
2nd	186/223	161	57	26 (13, 13)	25 (13, 12)	Male 3
3rd	61/87	56	35	15 (9, 6)	15 (9, 6)	Male 1
Total	306/373	216	107	50 (25, 25)	49 (25, 24)	Male 4

[0081]

All of the four Founder mice were male. Two lines (Nos. 30 and 31) of these four resulted in four and 20 offspring (F1 mice), respectively. The F1 mice thus obtained were genotyped, and three offspring in line 30 were found to be Tgm, indicating inheritance of the gp64 gene to the second generation. On the other hand, in line 31, all 20 offspring were found to be wild type mice (non-Tgm), in which the gp64 gene could not be detected. Accordingly, the gp64 gene was considered to be integrated into the line 31 Founder mouse in a mosaic structure. Founder mice of lines 34 and 46 had no fertility properties, and therefore, offspring were not obtained. Although the Founder mouse of line 30 impregnated one recipient female immediately after the initiation of crossing, no further offspring was obtained after that (Table 2).

15 [0082]

[Table 2]

Line No.	Date of birth	Sex	Copy Number of the introduced gene	Offspring obtained (date of birth, total offspring, and Tg)			Notes
30	010709	Male	More than 10 copies	010926	Female 3, Male 1	Female 3	No offspring were obtained after the first delivery. Testes are small and sperm are not observed.
31	010709	Male	2 to 3 copies	010927	Female 3, Male 5	0	Mosaic for gene transfer
				011022	Male 2	0	
				011108	Female 4, Male 6	0	
34	010709	Male	2 to 3 copies	No fertility properties	-	-	Testes are small and sperm are not observed.
46	010821	Male	2 to 3 copies	No fertility properties	-	-	Testes are small and sperm are not observed.

[0083]

Consequently, sperm from the Founder mice of lines 30, 34, and 46 was extracted in order to carry out *in vitro* fertilization. The testes of all three Founder mice were abnormally small (Fig. 3), and no sperm was observed in their cauda epididymidis. Thus *in vitro*

fertilization could not be achieved. From these results, the gp64 protein was found to affect the spermatogenic ability of mice. Therefore, it may be possible to use gp64 in contraception and such.

[0084]

5 3) Confirmation of the introduced gene

DNA was extracted from tails of three week-old mice using an automated nucleic acid isolation system (KURABO), and the presence of the introduced gene was confirmed by Southern blotting method and PCR. The introduced gene was confirmed by Southern blotting, as follows: First, 15 µg of genome DNA was digested with EcoRI, subjected to electrophoresis, and transferred to a nylon membrane. Then, the presence of the introduced gene was confirmed by hybridizing the transferred DNA with a probe, which was about 1.5 kb of EcoRI-digested fragment of pCAG-gp64 vector that comprises the gp64 gene. The presence of the introduced gene was also confirmed by the PCR method, using about 100 ng of DNA as a template, and primers comprising the sequences as shown below:

Sense primer (SEQ ID NO: 1): GAATTCCACCATGGTAAGCGCTATTGTT; and
Antisense primer (SEQ ID NO: 2): GAATTCTTAATATTGTCTATTACGGT.

20 PCR was carried out for:

5 minutes at 94°C;

35 cycles of "15 seconds at 94°C, 30 seconds at 57°C, and 30 seconds at 72°C";

7 minutes at 72°C; and

25 4°C forever.

The PCR products thus obtained were subjected to electrophoresis to confirm the introduced gene using the presence or absence of a band corresponding to about 1.5 kb as an indicator.

[0085]

30 4) Confirmation of the expression of the gp64 gene in gp64 Tgm

In the line 30 Founder mouse in which inheritance of the gp64 gene to the second generation had been confirmed, expression of the gp64 gene was confirmed by Northern blotting analysis. Specifically, total RNA was extracted from four kinds of organ, heart, brain, intestine, and a thigh muscle, by using ISOGEN (Nippon Gene). Then, 35 20 µg of the total RNA was subjected to electrophoresis, and was

transferred to a nylon membrane. An about 1.5 kb of EcoRI-digested fragment of pCAG-gp64 vector that comprises the gp64 gene was used as the probe for the Northern blotting analysis. An around 1.5 kb band corresponding to the gp64 gene was expected from the vector
5 construct.

Fig. 4 shows these results. Expression of the gp64 gene was confirmed at least in heart, brain, and thigh muscle. The reason why the bands were seen as three bands is unknown.

[0086]

10 5) Fertility properties of the line 30 female Tgm (crossing of mice)

When the line 30 female Tgm turned eight weeks-old, they were crossed with a male mouse of the same lineage.

As a result, a total of 31 (14 females and 17 males) offspring (F2) were obtained from two deliveries by each of the three F1 female
15 mice (Table 3). 14 of these offspring (five females and nine males) were Tgm. Since offspring were also obtained from the third delivery, the female Tgm were shown to have normal fertility properties.

[0087]

20 [Table 3]

Sex	Individual Number	Number of Deliveries	Offspring (Non-Tg)	Offspring (Tg)
Female	1	2	Female 3, Male 1	Female 1, Male 6
Female	2	2	Female 4, Male 3	Female 2, Male 1
Female	3	2	Female 2, Male 4	Female 2, Male 2

[0088]

6) Preparation of budding baculoviruses expressing PepT1

Budding baculoviruses expressing PepT1 and used as immunogens
25 were prepared as follows: PepT1 is a membrane protein that acts as a transporter. The PepT1 structure is known in the art (GenBank XM_007063, J. Biol. Chem. 270(12): 6456-6463 (1995)).

A full-length PepT1 gene was isolated from a human kidney

library using PCR. By inserting the full-length human PepT1 gene into pBlueBacHis2A (Invitrogen), the pBlueBacHis-PepT1 transfer vector was constructed. A Bac-N-Blue transfection kit (Invitrogen) was then used to introduce this transfer vector into Sf9 cells, along with
5 Bac-N-Blue DNA. Thus, a recombinant virus for the expression of human PepT1 was constructed. Specifically, 4 µg of pBlueBacHis-PepT1 was added to Bac-N-Blue DNA, and then 1 mL of Grace's medium (GIBCO) and 20 µL of cell FECTIN reagent was added. This was mixed, incubated for 15 minutes at room temperature, and then added drop-by-drop to
10 2x 10⁶ Sf9 cells washed once with Grace's medium. After incubating for four hours at room temperature, 2 mL of complete medium (Grace's medium which comprises 10% fetal bovine serum (Sigma), 100 units/mL penicillin, and 100 µg/mL streptomycin (GIBCO-BRL)) was added and cultured at 27°C. Recombinant viruses for expressing human PepT1,
15 which were constructed by homologous recombination, were cloned twice according to the instructions attached to the kit. A virus stock of the recombinant viruses was thus obtained.

[0089]

Construction of budding-type viruses that express human PepT1
20 was carried out as follows: Specifically, 500 mL of Sf9 cells (2x 10⁶/mL) were infected with the recombinant viruses prepared as above, so as to achieve MOI= 5. After culturing at 27°C for three days, the culture supernatant was centrifuged for 15 minutes at 800x g, and the cells and cell debris were removed. The supernatant recovered
25 by centrifugation was centrifuged at 45,000x g for 30 minutes, and the precipitate was then suspended in PBS. The cellular components were removed by centrifuging for another 15 minutes at 800x g. The supernatant was again centrifuged at 45,000x g for 30 minutes, and the precipitate was again suspended in PBS. This suspension was the
30 budding virus fraction. Expression of PepT1 in the virus and on the Sf-9 cell membrane was confirmed by Western analysis using anti-His antibodies. In addition, protein concentration was measured using Dc Protein Assay kit (Bio-Rad), with BSA as the standard.

[0090]

35 7) Immunization of mice

Mice were immunized by subcutaneous injection with an immunogen,

which was emulsified according to the standard method using complete and incomplete Freund's adjuvants (Difco). Injection doses in the first and the second immunizations were 1 mg/mouse and 0.5 mg/mouse, respectively. The second immunization was given 14 days after the first immunization. Seventeen days after the first immunization, serum samples were taken from the mice by retro-orbital bleeding.

[0091]

8) Confirmation of immunotolerance to gp64 by Western blotting analysis

10 PepT1-BV (1 µg/lane) was subjected to SDS-PAGE analysis on 12% gel under reducing conditions. After the electrophoresis, proteins were electroblotted onto a PVDF membrane. This membrane was reacted with 1,000 fold-diluted serum samples, sequentially washed, and then reacted with a 1,000 fold-diluted Biotin-Anti-Mouse IgG(γ) (Zymed) and Streptavidin-Alkaline Phosphatase (Zymed). An alkaline phosphatase staining kit (Nakarai) was used for staining. A positive control antibody for detecting gp64 was purchased from NOVAGEN.

20 Fig. 5 shows the results. When stained with the Anti-Mouse IgG, a band corresponding to the gp64 protein was strongly stained for the lanes reacted with both of the two serum samples obtained from non-transgenic mice. On the other hand, though gp64 was detected in all three gp64 transgenic mice, staining was weak. These results indicate that the amount of anti-gp64 antibody produced by the transgenic mice is considerably less than that produced by non-transgenic mice. Although the Anti-Mouse IgM staining was weak for the two non-transgenic mice, it was very weak or not stained at all in the gp64 transgenic mice (Fig. 6).

[0092]

8) Production of anti-PepT1 antibodies by gp64 Tgm

30 Following procedures were used for the initial immunization. 200 µl PBS comprising 1 mg of PepT1-BV and 100 ng of pertussis toxin was subcutaneously injected into Tgm. For the second and subsequent immunizations, 0.5 mg of PepT1-BV suspension in PBS was subcutaneously injected.

35 Ba/F3 cells expressing PepT1 on the cell surface (herein after, referred to as Ba/F3-PepT1) and Ba/F3 cells expressing no PepT1 were

washed twice with PBS, respectively. 100 μ l of mouse serum sample that was 220 fold-diluted with PBS was added to 1×10^6 cells of each cell type, followed by reaction for 30 minutes on ice. After reaction, cells were washed once with 500 μ l PBS and 100 μ l of FITC-anti-mouse IgG 200 fold-diluted with PBS was added. This was allowed to react for 30 minutes on ice. After centrifugation, cells were suspended in 500 μ l of PBS and analyzed by FACS. Fig. 7 and 8 show the results of FACS analysis of a serum obtained from a mouse after the fifth immunization. In these figures, dotted lines and solid lines indicate results of transgenic and non-transgenic mice, respectively.

From these results, the titer of antibody reacting specifically with Pep-T1 was confirmed to be increased in the serum of mice immunized with PepT1-BV.

[0093]

15 [Effects of the Invention]

This invention enables efficient production of antibodies against target antigens, using target antigens that comprise background antigens. The antibody-production methods of the present invention are useful in producing antibodies by using immunogens in which contamination by background antigens is inevitable.

[0094]

For example, an exogenous gene expression system, known as the baculovirus expression system, is useful as a tool for obtaining recombinant proteins easily and in large quantities. In particular, when applied to membrane proteins, the baculovirus expression system is excellent in that the membrane proteins are obtainable with other viral envelope proteins in a state that maintains their structure. However, this expression system is also problematic in that, when using this expression product as the immunogen, gp64 acts as a background protein and interferes with the acquisition of antibodies against a target protein.

[0095]

By using the antibody-production methods of the present invention, it is possible to efficiently suppress the adverse effect of background antigens on the proteins prepared by the baculovirus expression system. As a result, anti-membrane protein antibodies can

be produced efficiently by using the membrane protein antigens, which can be obtained in large quantities using the baculovirus expression system, as target antigens.

[0096]

5 Membrane proteins include many functionally important proteins such as receptors and cell adhesive proteins. Therefore, antibodies that recognize membrane proteins are expected to play an important role in functional analysis, localization analysis, quantification, diagnosis, or the development of therapeutic agents that regulate
10 membrane protein activities.

[0097]

Preparation of membrane proteins applicable as immunogens has been thought to be difficult. However, by the present invention, large quantities of membrane proteins produced by, for example, the
15 baculovirus expression system, can be used as immunogens without removing background antigens. Consequently, many antibodies that recognize various membrane proteins and that have been considered to be difficult to produce can now be obtained very efficiently.

The antibody-production methods of the present invention
20 contribute to the functional analysis of membrane proteins and diagnosis using antibodies, and to the development of drugs based on the regulation of membrane protein activities.

[0098]

[Sequence Listing]

25

SEQUENCE LISTING

<110> CHUGAI SEIYAKU KABUSHIKI KAISHA

<120> A method for producing the antibody

30

<130> C1-A0210

<140>

<141>

35

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

5 <211> 28

<212> DNA

<213> Artificial Sequence

<220>

10 <223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 1

gaattccacc atggttaagcg ctattgtt

28

15

<210> 2

<211> 26

<212> DNA

20 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

25

<400> 2

gaattcttaa tattgtctat tacggt

26

30 <210> 3

<211> 1539

<212> DNA

<213> Baculovirus

35 <220>

<221> CDS

<222> (1)..(1539)

<400> 3

	atg gta agc gct att gtt tta tat gtg ctt ttg gcg gcg gcg gcg cat	48
5	Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala Ala Ala His	
	1 5 10 15	
	tct gcc ttt gcg gcg gag cac tgc aac gcg caa atg aag acg ggt ccg	96
	Ser Ala Phe Ala Ala Glu His Cys Asn Ala Gln Met Lys Thr Gly Pro	
10	20 25 30	
	tac aag att aaa aac ttg gac att acc ccg ccc aag gaa acg ctg caa	144
	Tyr Lys Ile Lys Asn Leu Asp Ile Thr Pro Pro Lys Glu Thr Leu Gln	
	35 40 45	
15	aag gac gtg gaa atc acc atc gtg gag acg gac tac aac gaa aac gtg	192
	Lys Asp Val Glu Ile Thr Ile Val Glu Thr Asp Tyr Asn Glu Asn Val	
	50 55 60	
20	att atc ggc tac aag ggg tac tac cag gcg tat gcg tac aac ggc ggc	240
	Ile Ile Gly Tyr Lys Gly Tyr Tyr Gln Ala Tyr Ala Tyr Asn Gly Gly	
	65 70 75 80	
	tcg ctg gat ccc aac aca cgc gtc gaa gaa acc atg aaa acg ctg aat	288
25	Ser Leu Asp Pro Asn Thr Arg Val Glu Glu Thr Met Lys Thr Leu Asn	
	85 90 95	
	gtg ggc aaa gag gat ttg ctt atg tgg agc atc agg cag cag tgc gag	336
	Val Gly Lys Glu Asp Leu Leu Met Trp Ser Ile Arg Gln Gln Cys Glu	
30	100 105 110	
	gtg ggc gaa gag ctg atc gac cgt tgg ggc agt gac agc gac gac tgt	384
	Val Gly Glu Glu Leu Ile Asp Arg Trp Gly Ser Asp Ser Asp Asp Cys	
	115 120 125	
35	ttt cgc gac aac gag ggc cgc ggc cag tgg gtc aaa ggc aaa gag ttg	432

	Phe Arg Asp Asn Glu Gly Arg Gly Gln Trp Val Lys Gly Lys Glu Leu	
	130	135 140
	gtg aag cgg cag aat aac aat cac ttt gcg cac cac acg tgc aac aaa	480
5	Val Lys Arg Gln Asn Asn Asn His Phe Ala His His Thr Cys Asn Lys	
	145	150 155 160
	tcg tgg cga tgc ggc att tcc act tcg aaa atg tac agc agg ctc gag	528
10	Ser Trp Arg Cys Gly Ile Ser Thr Ser Lys Met Tyr Ser Arg Leu Glu	
		165 170 175
	tgc cag gac gac acg gac gag tgc cag gta tac att ttg gac gct gag	576
	Cys Gln Asp Asp Thr Asp Glu Cys Gln Val Tyr Ile Leu Asp Ala Glu	
		180 185 190
15	ggc aac ccc atc aac gtg acc gtg gac act gtg ctt cat cga gac ggc	624
	Gly Asn Pro Ile Asn Val Thr Val Asp Thr Val Leu His Arg Asp Gly	
		195 200 205
20	gtg agt atg att ctc aaa caa aag tct acg ttc acc acg cgc caa ata	672
	Val Ser Met Ile Leu Lys Gln Lys Ser Thr Phe Thr Thr Arg Gln Ile	
		210 215 220
	aaa gct gcg tgt ctg ctc att aaa gat gac aaa aat aac ccc gag tcg	720
25	Lys Ala Ala Cys Leu Leu Ile Lys Asp Asp Lys Asn Asn Pro Glu Ser	
		225 230 235 240
	gtg aca cgc gaa cac tgt ttg att gac aat gat ata tat gat ctt tct	768
	Val Thr Arg Glu His Cys Leu Ile Asp Asn Asp Ile Tyr Asp Leu Ser	
30		245 250 255
	aaa aac acg tgg aac tgc aag ttt aac aga tgc att aaa cgc aaa gtc	816
	Lys Asn Thr Trp Asn Cys Lys Phe Asn Arg Cys Ile Lys Arg Lys Val	
		260 265 270
35	gag cac cga gtc aag aag cgg ccg ccc act tgg cgc cac aac gtt aga	864

	Glu His Arg Val Lys Lys Arg Pro Pro Thr Trp Arg His Asn Val Arg	
	275	280 285
	gcc aag tac aca gag gga gac act gcc acc aaa ggc gac ctg atg cat 912	
5	Ala Lys Tyr Thr Glu Gly Asp Thr Ala Thr Lys Gly Asp Leu Met His	
	290	295 300
	att caa gag gag ctg atg tac gaa aac gat ttg ctg aaa atg aac att 960	
	Ile Gln Glu Glu Leu Met Tyr Glu Asn Asp Leu Leu Lys Met Asn Ile	
10	305	310 315 320
	gag ctg atg cat gcg cac atc aac aag cta aac aat atg ctg cac gac 1008	
	Glu Leu Met His Ala His Ile Asn Lys Leu Asn Asn Met Leu His Asp	
	325	330 335
15	ctg ata gtc tcc gtg gcc aag gtg gac gag cgt ttg att ggc aat etc 1056	
	Leu Ile Val Ser Val Ala Lys Val Asp Glu Arg Leu Ile Gly Asn Leu	
	340	345 350
20	atg aac aac tct gtt tct tca aca ttt ttg tgc gac gac acg ttt ttg 1104	
	Met Asn Asn Ser Val Ser Ser Thr Phe Leu Ser Asp Asp Thr Phe Leu	
	355	360 365
	ctg atg ccg tgc acc aat ccg ccg gca cac acc agt aat tgc tac aac 1152	
25	Leu Met Pro Cys Thr Asn Pro Pro Ala His Thr Ser Asn Cys Tyr Asn	
	370	375 380
	aac agc atc tac aaa gaa ggg cgt tgg gtg gcc aac acg gac tgc tgc 1200	
	Asn Ser Ile Tyr Lys Glu Gly Arg Trp Val Ala Asn Thr Asp Ser Ser	
30	385	390 395 400
	caa tgc ata gat ttt agc aac tac aag gaa cta gca att gac gac gac 1248	
	Gln Cys Ile Asp Phe Ser Asn Tyr Lys Glu Leu Ala Ile Asp Asp Asp	
	405	410 415
35	gtc gag ttt tgg atc ccg acc atc ggc aac acg acc tat cac gac agt 1296	

Val Glu Phe Trp Ile Pro Thr Ile Gly Asn Thr Thr Tyr His Asp Ser
 420 425 430

5 tgg aaa gat gcc agc ggc tgg tcg ttt att gcc caa caa aaa agc aac 1344
 Trp Lys Asp Ala Ser Gly Trp Ser Phe Ile Ala Gln Gln Lys Ser Asn
 435 440 445

10 ctc ata acc acc atg gag aac acc aag ttt ggc ggc gtc ggc acc agt 1392
 Leu Ile Thr Thr Met Glu Asn Thr Lys Phe Gly Gly Val Gly Thr Ser
 450 455 460

ctg agc gac atc act tcc atg gct gaa ggc gaa ttg gcc gct aaa ttg 1440
 Leu Ser Asp Ile Thr Ser Met Ala Glu Gly Glu Leu Ala Ala Lys Leu
 465 470 475 480

15 act tcg ttc atg ttt ggt cat gta gtt aac ttt gta att ata tta att 1488
 Thr Ser Phe Met Phe Gly His Val Val Asn Phe Val Ile Ile Leu Ile
 485 490 495

20 gtg att tta ttt ttg tac tgt atg att aga aac cgt aat aga caa tat 1536
 Val Ile Leu Phe Leu Tyr Cys Met Ile Arg Asn Arg Asn Arg Gln Tyr
 500 505 510

25 taa 1539

<210> 4
 <211> 512
 30 <212> PRT
 <213> Baculovirus

<400> 4
 Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala Ala Ala His
 35 1 5 10 15
 Ser Ala Phe Ala Ala Glu His Cys Asn Ala Gln Met Lys Thr Gly Pro

	20	25	30
	Tyr Lys Ile Lys Asn Leu Asp Ile Thr Pro Pro Lys Glu Thr Leu Gln		
	35	40	45
	Lys Asp Val Glu Ile Thr Ile Val Glu Thr Asp Tyr Asn Glu Asn Val		
5	50	55	60
	Ile Ile Gly Tyr Lys Gly Tyr Tyr Gln Ala Tyr Ala Tyr Asn Gly Gly		
	65	70	75
	Ser Leu Asp Pro Asn Thr Arg Val Glu Glu Thr Met Lys Thr Leu Asn		
	85	90	95
10	Val Gly Lys Glu Asp Leu Leu Met Trp Ser Ile Arg Gln Gln Cys Glu		
	100	105	110
	Val Gly Glu Glu Leu Ile Asp Arg Trp Gly Ser Asp Ser Asp Asp Cys		
	115	120	125
	Phe Arg Asp Asn Glu Gly Arg Gly Gln Trp Val Lys Gly Lys Glu Leu		
15	130	135	140
	Val Lys Arg Gln Asn Asn Asn His Phe Ala His His Thr Cys Asn Lys		
	145	150	155
	Ser Trp Arg Cys Gly Ile Ser Thr Ser Lys Met Tyr Ser Arg Leu Glu		
	165	170	175
20	Cys Gln Asp Asp Thr Asp Glu Cys Gln Val Tyr Ile Leu Asp Ala Glu		
	180	185	190
	Gly Asn Pro Ile Asn Val Thr Val Asp Thr Val Leu His Arg Asp Gly		
	195	200	205
	Val Ser Met Ile Leu Lys Gln Lys Ser Thr Phe Thr Thr Arg Gln Ile		
25	210	215	220
	Lys Ala Ala Cys Leu Leu Ile Lys Asp Asp Lys Asn Asn Pro Glu Ser		
	225	230	235
	Val Thr Arg Glu His Cys Leu Ile Asp Asn Asp Ile Tyr Asp Leu Ser		
	245	250	255
30	Lys Asn Thr Trp Asn Cys Lys Phe Asn Arg Cys Ile Lys Arg Lys Val		
	260	265	270
	Glu His Arg Val Lys Lys Arg Pro Pro Thr Trp Arg His Asn Val Arg		
	275	280	285
	Ala Lys Tyr Thr Glu Gly Asp Thr Ala Thr Lys Gly Asp Leu Met His		
35	290	295	300
	Ile Gln Glu Glu Leu Met Tyr Glu Asn Asp Leu Leu Lys Met Asn Ile		

	305		310		315		320									
	Glu	Leu	Met	His	Ala	His	Asn	Lys	Leu	Asn	Asn	Met	Leu	His	Asp	
				325				330					335			
	Leu	Ile	Val	Ser	Val	Ala	Lys	Val	Asp	Glu	Arg	Leu	Ile	Gly	Asn	Leu
5			340					345					350			
	Met	Asn	Asn	Ser	Val	Ser	Ser	Thr	Phe	Leu	Ser	Asp	Asp	Thr	Phe	Leu
			355					360					365			
	Leu	Met	Pro	Cys	Thr	Asn	Pro	Pro	Ala	His	Thr	Ser	Asn	Cys	Tyr	Asn
			370					375					380			
10	Asn	Ser	Ile	Tyr	Lys	Glu	Gly	Arg	Trp	Val	Ala	Asn	Thr	Asp	Ser	Ser
	385					390						395				400
	Gln	Cys	Ile	Asp	Phe	Ser	Asn	Tyr	Lys	Glu	Leu	Ala	Ile	Asp	Asp	Asp
				405								410				415
	Val	Glu	Phe	Trp	Ile	Pro	Thr	Ile	Gly	Asn	Thr	Thr	Tyr	His	Asp	Ser
15			420					425					430			
	Trp	Lys	Asp	Ala	Ser	Gly	Trp	Ser	Phe	Ile	Ala	Gln	Gln	Lys	Ser	Asn
			435					440					445			
	Leu	Ile	Thr	Thr	Met	Glu	Asn	Thr	Lys	Phe	Gly	Gly	Val	Gly	Thr	Ser
			450					455					460			
20	Leu	Ser	Asp	Ile	Thr	Ser	Met	Ala	Glu	Gly	Glu	Leu	Ala	Ala	Lys	Leu
	465							470					475			480
	Thr	Ser	Phe	Met	Phe	Gly	His	Val	Val	Asn	Phe	Val	Ile	Ile	Leu	Ile
				485									490			495
	Val	Ile	Leu	Phe	Leu	Tyr	Cys	Met	Ile	Arg	Asn	Arg	Asn	Arg	Gln	Tyr
25			500										505			510

[Brief Description of the Drawings]

[Fig. 1]

Fig. 1 shows the nucleotide sequence of the constructed gp64 gene.

5 [Fig. 2]

Fig. 2 shows the structure of the pCAG-gp64 vector constructed in Examples.

[Fig. 3]

Fig. 3 is a photograph of the Founder mice testes.

10 [Fig. 4]

Fig. 4 is a photograph showing the result of mRNA expression analysis by Northern blotting. In this figure, H, B, I, and M refer to heart, brain, intestine, and muscle, respectively.

[Fig. 5]

15 Fig. 5 is a photograph showing the results of Western blotting analysis using anti-mouse IgG. In this figure, "pre" and "2nd" respectively refer to pre-immunization blood collection, and blood collection after the second immunization. Gp64TgM and wtBALB/c represent transgenic and non-transgenic mice, respectively.

20 [Fig. 6]

Fig. 6 is a photograph showing the results of Western blotting analysis using anti-mouse IgG. Gp64TgM and wtBALB/c represent transgenic and non-transgenic mice, respectively.

[Fig. 7]

25 Fig. 7 shows the result of FACS analysis of the antibody titer for PepT1-specific antibody in the mouse serum. In this figure, the x-axis and y-axis respectively represent cell number (log scale) and fluorescence intensity. (Above) mouse #1; (below) mouse #2.


[Fig. 8]

30 Fig. 8 shows the results of the same analysis in Fig. 8. (Above) mouse #3; (below) no antibody.

[Fig. 1]


254-107	21	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000
---------	----	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------

[Fig. 2]




BEST AVAILABLE COPY

[Fig. 3]




BEST AVAILABLE COPY

[Fig. 4]




[Fig. 5]



BEST AVAILABLE COPY


[Fig. 6]




BEST AVAILABLE COPY

[Fig. 7]

MOUSE #1




MOUSE #2




[Fig. 8]

MOUSE #3



NO ANTIBODY



[Document Name] Abstract

[Problems to Be Solved]

5 An objective of this invention is to provide methods for
producing antibodies that enable target antibodies to be easily
obtained. In addition, an objective of this invention is to provide
transgenic non-human animals that efficiently produce subject
antibodies.

[Means to Solve the Problems]

10 This invention provides methods for producing antibodies,
wherein the methods comprise the step of administering an immunogen
comprising both a target antigen and a background antigen to
transgenic animals, into which a gene coding for the background
antigen has been introduced. Since immunotolerance to the background
antigens have thus been induced in the transgenic animals, the animals
15 efficiently produce antibodies to target antigens.

[Selected Drawings] None